Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 8/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786821 | 0.95 | SUV39H2 (0.39) | DRD2SUV39H2STING1BRD4MAPT | |
| SCHEMBL6794553 | 0.94 | DRD2 (0.41) | DRD2SUV39H2STING1BRD4DYRK1A | |
| SCHEMBL6791824 | 0.90 | DRD2 (0.41) | DRD2SUV39H2STING1BRD4DYRK1A | |
| SCHEMBL6791850 | 0.88 | SUV39H2 (0.41) | DRD2SUV39H2BRD4 | |
| SCHEMBL6787603 | 0.85 | SUV39H2 (0.41) | DRD2SUV39H2BRD4 | |
| SCHEMBL6787224 | 0.85 | DRD2 (0.40) | DRD2STING1BRD4DYRK1A | |
| SCHEMBL6792664 | 0.82 | DRD2 (0.38) | DRD2STING1BRD4DYRK1A | |
| SCHEMBL6790810 | 0.82 | DRD2 (0.38) | DRD2STING1BRD4DYRK1A | |
| SCHEMBL6787885 | 0.82 | DRD2 (0.37) | DRD2STING1BRD4DYRK1A | |
| SCHEMBL6793980 | 0.81 | LATS1 (0.37) | DRD2STING1BRD4DYRK1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | DRD2 4396/4885SUV39H2 3165/4885STING1 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.